시장보고서
상품코드
1283954

마이크로바이옴 치료제 시장 규모, 시장 점유율, 용도 분석, 지역별 전망, 성장 동향, 주요 기업, 경쟁 전략, 예측(2023-2031년)

Microbiome Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 To 2031

발행일: | 리서치사: Acute Market Reports | 페이지 정보: 영문 117 Pages | 배송안내 : 1-2일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

마이크로바이옴 치료제 시장은 2031년까지 32% 성장할 것으로 예상됩니다. 마이크로바이옴 치료제 시장은 오늘날 세계에서 풍부한 기회를 가진 신흥 시장입니다. 시장 전문가들은 예측 기간 중 임상시험에 참여하는 제품의 수는 마이크로바이옴 치료제에 초점을 맞춘 연구개발 활동이 세계에서 이루어지고 있음을 증명하고 있다고 지적합니다. 마이크로바이옴 시장의 구조를 고려할 때 그 잠재력은 매우 큽니다. 이 시장의 성장을 지원하는 주요 요인은 노인 인구 증가, 생활습관병 증가, 고효율 및 부작용이 적은 치료법에 대한 수요 증가 등입니다. 반면, 시장 성장을 억제하는 주요 요인으로는 시장 개척을 위한 광범위한 연구 부족, 프리바이오틱스와 프로바이오틱스의 효율적인 사용과 효과에 대한 대중의 낮은 인식, 프로바이오틱스와 프리바이오틱스에 대한 정부의 규제 강화가 시급한 상황 등이 있습니다. 마이크로바이옴 시장 세분화는 약물 유형, 질병, 지역으로 구성됩니다.

시장 전문가에 따르면 인체 미생물 환경은 2010년 이후 6억 5,000만 달러 이상을 유치했다고 말합니다. 최근 수년간 프로바이오틱스, 즉 유익한 장내 세균 요법이 인기를 끌고 있습니다. 이 제품들은 인간의 마이크로바이옴을 자연 상태로 되돌리고 많은 질병을 예방할 수 있는 능력을 가지고 있습니다. 그러나 전체 마이크로바이옴 치료제 시장은 아직 개발 중이기 때문에 약물을 대체하거나 질병을 근절하기 위한 치료법으로 사용할 수 없습니다. 마이크로바이옴 치료제의 지역별 시장 규모는 유럽이 가장 크고 북미가 그 뒤를 이을 것으로 보입니다. 유럽의 마이크로바이옴 치료제 시장을 이끄는 주요 요인은 프로바이오틱스 및 프리바이오틱스 제품에 대한 높은 수용성과 인지도 상승에 기인하는 것으로 보입니다. 아시아태평양은 예측 기간 중 인구 및 질병 유병률 측면에서 가장 잠재력이 높은 지역으로 확인되었습니다.

목차

제1장 서문

  • 리포트 내용
    • 보고서의 목적
    • 대상 독자
    • 주요 제공 상품
  • 시장 세분화
  • 조사 방법
    • 단계 I - 2차 조사
    • 단계 II - 1차 조사
    • 단계 III - 전문가 패널 리뷰
    • 전제조건
    • 채택한 어프로치

제2장 주요 요약

  • 시장 스냅숏 : 세계의 마이크로바이옴 치료제 시장
  • 유형별 세계의 마이크로바이옴 치료제 시장 2022
  • 용도별 세계의 마이크로바이옴 치료제 시장 2022
  • 지역별 세계의 마이크로바이옴 치료제 시장 2022
  • 매력적인 투자 제안 : 지역별 2022

제3장 마이크로바이옴 치료제 시장 : 경쟁 분석

  • 주요 벤더의 시장 포지셔닝
  • 벤더가 채택한 전략
  • 주요 산업 전략
  • Tier 분석 : 2022 vs 2031

제4장 마이크로바이옴 치료제 시장 : 거시적 분석과 시장 역학

  • 서론
  • 세계의 마이크로바이옴 치료제 시장 가치 2021-2031
  • 시장 역학
    • 시장 촉진요인
    • 시장 억제요인
    • 주요 과제
    • 주요 기회
  • 촉진요인과 억제요인의 영향 분석
  • 시소 분석

제5장 마이크로바이옴 치료제 시장, 유형별 : 2021-2031

  • 시장 개요
  • 성장·매출 분석 : 2022 vs 2031
  • 시장 세분화
    • FMT
    • 마이크로바이옴약

제6장 마이크로바이옴 치료제 시장, 용도별 : 2021-2031

  • 시장 개요
  • 성장·매출 분석 : 2022 vs 2031
  • 시장 세분화
    • C. 디피실
    • 크론병
    • 염증성장질환
    • 당뇨병
    • 기타

제7장 북미의 마이크로바이옴 치료제 시장 : 2021-2031

  • 시장 개요
  • 마이크로바이옴 치료제 시장, 유형별 : 2021-2031
  • 마이크로바이옴 치료제 시장, 용도별 : 2021-2031
  • 마이크로바이옴 치료제 시장, 지역별 : 2021-2031
    • 북미
      • 미국
      • 캐나다
      • 기타 북미 지역

제8장 영국 및 유럽연합의 마이크로바이옴 치료제 시장 : 2021-2031

  • 시장 개요
  • 마이크로바이옴 치료제 시장, 유형별 : 2021-2031
  • 마이크로바이옴 치료제 시장, 용도별 : 2021-2031
  • 마이크로바이옴 치료제 시장, 지역별 : 2021-2031
    • 영국과 유럽연합
      • 영국
      • 독일
      • 스페인
      • 이탈리아
      • 프랑스
      • 기타 유럽 지역

제9장 아시아태평양의 마이크로바이옴 치료제 시장 : 2021-2031

  • 시장 개요
  • 마이크로바이옴 치료제 시장, 유형별 : 2021-2031
  • 마이크로바이옴 치료제 시장, 용도별 : 2021-2031
  • 마이크로바이옴 치료제 시장, 지역별 : 2021-2031
    • 아시아태평양
      • 중국
      • 일본
      • 인도
      • 호주
      • 한국
      • 기타 아시아태평양

제10장 라틴아메리카의 마이크로바이옴 치료제 시장 : 2021-2031

  • 시장 개요
  • 마이크로바이옴 치료제 시장, 유형별 : 2021-2031
  • 마이크로바이옴 치료제 시장, 용도별 : 2021-2031
  • 마이크로바이옴 치료제 시장, 지역별 : 2021-2031
    • 라틴아메리카
      • 브라질
      • 멕시코
      • 기타 라틴아메리카 지역

제11장 중동 및 아프리카의 마이크로바이옴 치료제 시장 : 2021-2031

  • 시장 개요
  • 마이크로바이옴 치료제 시장, 유형별 : 2021-2031
  • 마이크로바이옴 치료제 시장, 용도별 : 2021-2031
  • 마이크로바이옴 치료제 시장, 지역별 : 2021-2031
    • 중동 및 아프리카
      • GCC
      • 아프리카
      • 기타 중동 및 아프리카

제12장 기업 개요

  • OpenBiome
  • Seres Therapeutics Inc.
  • 4D Pharma plc.
  • Locus Biosciences Inc.
  • Enterome SA
  • Finch Therapeutics Group Inc.
  • Intralytix Inc.
  • Microbiotica
  • Second Genome
  • Rebiotix Inc.
  • Vedanta Bioscience Inc.
  • 기타 주목 기업
KSA 23.06.15

Microbiome Therapeutics Market is Expected to Grow at 32% by 2031. Microbiome therapeutics market is an emerging market with abundant opportunities in today's world. During the forecast period market experts suggest that number of products currently involved in clinical trials proves the amount of research and development activities carried out across the world focusing on microbiome therapeutics. Considering the structure of the microbiome market the potential is quite large. The key factors assisting the growth of this market comprise rising geriatric population, increasing incidences of lifestyle diseases, increasing demand for treatments with high efficiency and low side effects. The major factors that are expected to restrain the growth of this market are lack of broad research to aid the market pull, low awareness among the population related to the efficient usage and effect of prebiotics and probiotics, and impending government regulations on probiotics and prebiotics. The segmentation of microbiome market comprises of type of drugs, diseases, and geography.

Market experts suggest that the microbial landscape of human body has attracted more than US$ 650 Mn since 2010. In recent years, probiotics, or beneficial gut bacteria therapy, have been popular. These products possess capacity of preventing number of diseases by restoring the human microbiome to its natural state. However, the overall microbiome therapeutics market is still in its infancy; hence, cannot be used as a replacement for medication or as a treatment for the eradication of the disease. Europe was observed as the leading regional market for microbiome therapeutics followed by North America. The key factors assisting the microbiome therapeutics market in Europe are due to high acceptance and rising awareness of probiotic and prebiotic products. Asia-Pacific was observed as the most potential region in terms of population and prevalence of disease throughout the forecast period.

Key Players Identified for Microbiome Therapeutics Market Include but are Not Limited to:

OpenBiome, Seres Therapeutics Inc., 4D Pharma plc., Locus Biosciences, Inc., Enterome SA, Finch Therapeutics Group, Inc., Intralytix, Inc., Microbiotica, Second Genome, Rebiotix Inc., Vedanta Bioscience, Inc. And Other Notable Players.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Microbiome Therapeutics market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Microbiome Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

  • FMT
  • Microbiome Drugs

Application

  • C. difficile
  • Crohn's disease
  • Inflammatory Bowel Disease
  • Diabetes
  • Others

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Microbiome Therapeutics market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Microbiome Therapeutics market?
  • Which is the largest regional market for Microbiome Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Microbiome Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Microbiome Therapeutics market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Microbiome Therapeutics Market
  • 2.2. Global Microbiome Therapeutics Market, By Type, 2022 (US$ Million)
  • 2.3. Global Microbiome Therapeutics Market, By Application, 2022 (US$ Million)
  • 2.4. Global Microbiome Therapeutics Market, By Geography, 2022 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2022

3. Microbiome Therapeutics Market: Competitive Analysis

  • 3.1. Market Positioning of Key Microbiome Therapeutics Market Vendors
  • 3.2. Strategies Adopted by Microbiome Therapeutics Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Microbiome Therapeutics Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Microbiome Therapeutics Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. FMT
    • 5.3.2. Microbiome Drugs

6. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. C. difficile
    • 6.3.2. Crohn's disease
    • 6.3.3. Inflammatory Bowel Disease
    • 6.3.4. Diabetes
    • 6.3.5. Others

7. North America Microbiome Therapeutics Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
  • 7.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
  • 7.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 7.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 7.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 7.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

8. UK and European Union Microbiome Therapeutics Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
  • 8.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
  • 8.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.4.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.5.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.6.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

9. Asia Pacific Microbiome Therapeutics Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
  • 9.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
  • 9.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.4.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.5.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.6.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

10. Latin America Microbiome Therapeutics Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
  • 10.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
  • 10.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 10.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 10.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 10.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

11. Middle East and Africa Microbiome Therapeutics Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
  • 11.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
  • 11.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 11.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 11.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 11.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

12. Company Profile

  • 12.1. OpenBiome
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Seres Therapeutics Inc.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. 4D Pharma plc.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Locus Biosciences, Inc.
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Enterome SA
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Finch Therapeutics Group, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Intralytix, Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Microbiotica
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Second Genome
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Rebiotix Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Vedanta Bioscience, Inc.
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
  • 12.12. Other Notable Players
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제